Nicotinamide Riboside in LVAD Recipients (PilotNR-LVAD)
Heart Failure,Congestive, Heart Failure New York Heart Association Class IV, Mitochondrial Alteration

About this trial
This is an interventional treatment trial for Heart Failure,Congestive
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of advanced heart failure.
- Planned elective LVAD implantation surgery with patient agreements for candidacy in place as required by UWMC.
- Hospital inpatient at time of enrollment.
- Ability to undergo Study procedures.
- Willingness/ability to provide informed consent.
Exclusion Criteria:
- Current smoking
- Receiving certain concurrent supplements (to be determined at discretion of the PI). Note that UWMC Nutrition Care standards call for a general multivitamin (1 tab PO daily) as part of the advanced heart failure therapy (AHFT) work-up.
- Known allergies to niacin or nicotinamide.
- Hepatic, renal, endocrine, or neurological disease that disqualify them from consideration for LVAD implantation.
- Inability to perform Study visits or procedures.
- Unwillingness/inability to provide informed consent.
- Women who are currently pregnant or who wish to become pregnant over the course of the study follow-up are not allowed to join this study. This exclusion is built into the LVAD candidate selection process.
Sites / Locations
- University of Washington
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Open-label nicotinamide riboside
Baseline controls
Participants scheduled to receive an LVAD will be prescribed nicotinamide riboside (NR) according to the following administration schedule: Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg) Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily Washout Day of LVAD Surgery and/or Day 15: None
Patients previously receiving LVADs, in whom blood and myocardial tissue assays for NAD+ levels and mitochondrial function were performed.